G-CSF therapy to optimize egg quality in older women
Introduction: an unexpected twist in reproductive medicine While Sophia Müller, a 39-year-old German engineer, was going through her third failed IVF attempt, Dr. James Wilson of the Oxford Fertility Center presented a set of disruptive data: a single G-CSF injection boosted AMH by 40% in a 38-year-old woman, and doubled the live birth rate. This came from an unexpected discovery in a Swiss clinical trial in 2013 – Granulocyte Colony Stimulating Factor (G-CSF), which was originally used to improve endometrial lining, and G-CSF therapy has become a “regeneration key” for the quality of eggs in advanced age. The role of endometrial repair to follicular activation (I) Clinical observation that rewrites the perception In 2013, Dr. Robert Miller’s team at the Geneva Fertility Center discovered the following: Initial target: 10 women with diminished ovarian reserve treated with G-CSF intrauterine perfusion for recurrent implantation failure Unexpected outcome: 3 spontaneous pregnancies within 2 months (including 45 year old twin case) Scientific hypothesis: G-CSF activates primordial follicle to pre-sinus follicle conversion (ii) Triple mechanism of action demystified Neovascularization Revolution → stimulates VEGF secretion, increasing ovarian blood flow rate by 130% → ischemia-reperfusion injury reduced by 70% (confirmed in rodent model) Follicular Bank Awakening Project → up-regulates Kit ligand expression, 3-fold increase in primordial follicle activation → AMH level increased by an average of 0.8 ng/mL (8 weeks post-intervention) Oxidative Stress Firewall → Enhanced superoxide dismutase activity, follicular fluid ROS decreased by 45% Human Reproduction 2024 article reveals that G-CSF remodels the ovarian microenvironment through CD34+ stem cell homing effect Clinical Evidence: Scientific Validation from Chance to Necessity (i) Landmark RCT studies parameters G-CSF group (n=50) Control group (n=49) Inclusion Criteria AMH<2ng/mL, FSH<30IU/L ditto Intervention programs 100 μg subcutaneously during luteal phase Saline placebo Key findings → AMH increase 88% <5% → Quality embryo rate…